JP2000515002A - 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 - Google Patents
標的分子の活性部位またはクレフトと特異的に相互作用する認識分子Info
- Publication number
- JP2000515002A JP2000515002A JP09535650A JP53565097A JP2000515002A JP 2000515002 A JP2000515002 A JP 2000515002A JP 09535650 A JP09535650 A JP 09535650A JP 53565097 A JP53565097 A JP 53565097A JP 2000515002 A JP2000515002 A JP 2000515002A
- Authority
- JP
- Japan
- Prior art keywords
- recognition
- antigen
- recognition molecule
- molecule
- cab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims abstract description 50
- 239000000427 antigen Substances 0.000 claims description 91
- 108091007433 antigens Proteins 0.000 claims description 91
- 102000036639 antigens Human genes 0.000 claims description 91
- 108090000623 proteins and genes Proteins 0.000 claims description 64
- 150000001413 amino acids Chemical class 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 51
- 102000004190 Enzymes Human genes 0.000 claims description 41
- 108090000790 Enzymes Proteins 0.000 claims description 41
- 108020004705 Codon Proteins 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 13
- 108091026890 Coding region Proteins 0.000 claims description 10
- 239000003053 toxin Substances 0.000 claims description 10
- 231100000765 toxin Toxicity 0.000 claims description 10
- 108700012359 toxins Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 238000003780 insertion Methods 0.000 claims description 8
- 230000037431 insertion Effects 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 6
- 238000002823 phage display Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 239000013014 purified material Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 231100000699 Bacterial toxin Toxicity 0.000 claims description 2
- 239000000688 bacterial toxin Substances 0.000 claims description 2
- 230000037429 base substitution Effects 0.000 claims description 2
- 230000008827 biological function Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003998 snake venom Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000239290 Araneae Species 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 239000003659 bee venom Substances 0.000 claims 1
- 238000013507 mapping Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 42
- 229940088598 enzyme Drugs 0.000 description 39
- 235000018102 proteins Nutrition 0.000 description 38
- 241000282836 Camelus dromedarius Species 0.000 description 29
- 239000007924 injection Substances 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 25
- 102000016943 Muramidase Human genes 0.000 description 22
- 108010014251 Muramidase Proteins 0.000 description 22
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 22
- 229960000274 lysozyme Drugs 0.000 description 22
- 239000004325 lysozyme Substances 0.000 description 22
- 235000010335 lysozyme Nutrition 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 238000002965 ELISA Methods 0.000 description 19
- 238000007920 subcutaneous administration Methods 0.000 description 19
- 102000003846 Carbonic anhydrases Human genes 0.000 description 18
- 108090000209 Carbonic anhydrases Proteins 0.000 description 18
- 239000005018 casein Substances 0.000 description 16
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 16
- 235000021240 caseins Nutrition 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108010055044 Tetanus Toxin Proteins 0.000 description 14
- 229940118376 tetanus toxin Drugs 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 239000004382 Amylase Substances 0.000 description 11
- 102000013142 Amylases Human genes 0.000 description 11
- 108010065511 Amylases Proteins 0.000 description 11
- 235000019418 amylase Nutrition 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000011230 binding agent Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 9
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 230000002860 competitive effect Effects 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000004867 Hydro-Lyases Human genes 0.000 description 7
- 108090001042 Hydro-Lyases Proteins 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- 235000002198 Annona diversifolia Nutrition 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 101710120037 Toxin CcdB Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000003463 organelle Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282832 Camelidae Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 241000282838 Lama Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 description 4
- 102100026367 Pancreatic alpha-amylase Human genes 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 4
- 108090000637 alpha-Amylases Proteins 0.000 description 4
- 229940024171 alpha-amylase Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 210000003763 chloroplast Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- -1 phospho Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 101001106957 Bos taurus Ribonuclease pancreatic Proteins 0.000 description 3
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 3
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 239000007994 TES buffer Substances 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 239000002340 cardiotoxin Substances 0.000 description 3
- 231100000677 cardiotoxin Toxicity 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical group [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 102220054109 rs72474224 Human genes 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102100032566 Carbonic anhydrase-related protein 10 Human genes 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 101000867836 Homo sapiens Carbonic anhydrase-related protein 10 Proteins 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- 241000282842 Lama glama Species 0.000 description 2
- 101710132682 Lysozyme 1 Proteins 0.000 description 2
- 102100026863 Lysozyme-like protein 4 Human genes 0.000 description 2
- 108050000796 Lysozyme-like protein 4 Proteins 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 102220283785 rs1344101243 Human genes 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 1
- YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 1
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 101001023095 Anemonia sulcata Delta-actitoxin-Avd1a Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710126338 Apamin Proteins 0.000 description 1
- 101100325793 Arabidopsis thaliana BCA2 gene Proteins 0.000 description 1
- 101000641989 Araneus ventricosus Kunitz-type U1-aranetoxin-Av1a Proteins 0.000 description 1
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282828 Camelus bactrianus Species 0.000 description 1
- 102100033007 Carbonic anhydrase 14 Human genes 0.000 description 1
- 102100033029 Carbonic anhydrase-related protein 11 Human genes 0.000 description 1
- 101001028691 Carybdea rastonii Toxin CrTX-A Proteins 0.000 description 1
- 101000685083 Centruroides infamatus Beta-toxin Cii1 Proteins 0.000 description 1
- 101000685085 Centruroides noxius Toxin Cn1 Proteins 0.000 description 1
- 101001028688 Chironex fleckeri Toxin CfTX-1 Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 241000271532 Crotalus Species 0.000 description 1
- 241000271537 Crotalus atrox Species 0.000 description 1
- 101000644407 Cyriopagopus schmidti U6-theraphotoxin-Hs1a Proteins 0.000 description 1
- 101710190435 Cytotoxin 5 Proteins 0.000 description 1
- 241000272019 Dendroaspis polylepis polylepis Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000867862 Homo sapiens Carbonic anhydrase 14 Proteins 0.000 description 1
- 101000867841 Homo sapiens Carbonic anhydrase-related protein 11 Proteins 0.000 description 1
- 101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 241000272041 Naja Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101000679608 Phaeosphaeria nodorum (strain SN15 / ATCC MYA-4574 / FGSC 10173) Cysteine rich necrotrophic effector Tox1 Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010038081 SIV(mac) proteinase Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 101000794214 Staphylococcus aureus Toxic shock syndrome toxin-1 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- IDIPWEYIBKUDNY-UHFFFAOYSA-N benzenesulfonyl fluoride Chemical compound FS(=O)(=O)C1=CC=CC=C1 IDIPWEYIBKUDNY-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 108010091894 dendrotoxin K Proteins 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 229940099238 diamox Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- OSRUSFPMRGDLAG-QMGYSKNISA-N dorzolamide hydrochloride Chemical compound [Cl-].CC[NH2+][C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 OSRUSFPMRGDLAG-QMGYSKNISA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 101150118163 h gene Proteins 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 101150102226 hh gene Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- YVIIHEKJCKCXOB-STYWVVQQSA-N molport-023-276-178 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(N[C@@H](CSSC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N2)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)=O)CC(C)C)[C@@H](C)O)C(N)=O)C1=CNC=N1 YVIIHEKJCKCXOB-STYWVVQQSA-N 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 102220201545 rs886041401 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000002708 spider venom Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.基本認識ユニットから伸びた露出したループ構造を特徴とする、標的分子 の活性部位またはクレフトと相互作用する能力を有する、可能な認識分子。 2.ループ構造が、標的分子の活性部位またはクレフトに対する結合特異性を 有するラクダ科の重鎖抗体のCDR3またはこのようなCDR3の誘導バージョ ンである、請求項1記載の認識分子。 3.CDR3の誘導バージョンが、少なくとも一つの天然アミノ酸が、1個ま たはそれ以上の他のアミノ酸によって置換されている突然変異CDR3である、 請求項1または2記載の認識分子。 4.CDR3の誘導バージョンが、1個またはそれ以上の追加のアミノ酸が付 加されるかおよび/またはその天然アミノ酸配列内に組み込まれている突然変異 CDR3である、請求項1または2記載の認識分子。 5.基本認識ユニットが、標的分子に対する結合親和性をもつ抗体型構造によ って形成されている、請求項1から4に記載の認識分子。 6.抗体型構造が、ラクダ科重鎖抗体またはその修飾バージョンの少なくとも 一部によって形成されている、請求項5に記載の認識分子。 7.ラクダ科抗体の修飾バージョンが、少なくとも一つの天然アミノ酸が、1 個またはそれ以上の他のアミノ酸によって置換されているバージョンである、請 求項6に記載の認識分子。 8.ラクダ科抗体の修飾バージョンが、1個またはそれ以上の追加のアミノ酸 が付加されるかおよび/またはその天然アミノ酸配列内に組み込まれているバー ジョンを含む、請求項6または7に記載の認識分子。 9.ラクダ科抗体の修飾バージョンが、第二のアミノ酸配列に融合しているバ ージョンである、請求項6、7または8に記載の認識分子。 10.ラクダ科抗体の修飾バージョンが、生物学的に活性な分子に連結してい るバージョンである、請求項6、7または8に記載の認識分子。 11.標的分子の生物学的機能の中和において使用する、請求項1から10に 記載の認識分子。 12.治療、診断、ワクチンおよび標的分子の単離または精製において使用す る、請求項1から10に記載の認識分子。 13.標的分子が、細菌毒素、ヘビ毒液由来の毒素、ミツバチ毒液由来の毒素 、クモ毒素、酵素、特にウイルスおよび細菌の酵素、ならびに受容体から選ばれ る、請求項11または12に記載の認識分子。 14.1種またはそれ以上の請求項1から13に記載の認識分子および適当な 賦形剤を含む、治療用組成物。 15.1種またはそれ以上の請求項1から13に記載の認識分子含む、診断用 試験キット。 16.1種またはそれ以上の請求項1から13に記載の認識分子を含むワクチ ン。 17.担体に結合した1種またはそれ以上の請求項1から13に記載の認識分 子を有する該担体からなる精製材料。 18.担体がカラム材料であり、好ましくは親和性カラムである、請求項17 記載の精製材料。 19.抗原に特異的である、請求項1から13に記載の認識分子の製造方法で あって: a)ラクダ科重鎖抗体を準備し; b)コーディング配列を単離し、ファージディスプレイベクターにおいてクロ ーニングし; c)該ベクターを宿しているファージにおいて該コーディング配列を発現し; 次いで d)ファージを固定抗原で選り分けることによって抗原に特異的な認識分子を 選択すること、を特徴とする方法。 20.抗原に特異的である、請求項1から13に記載の認識分子の製造方法で あって: a)ラクダ科重鎖抗体をランダムに選び; b)コーディング配列を単離し、ファージディスプレイベクターにおいてクロ ーニングし; c)該コーディング配列を少なくともひとつのコドンにおいてランダムに置換 することにより修飾し; d)ファージディスプレイベクターにおいてランダムに突然変異したコーディ ング配列のライブラリを作成し; e)該ベクターを宿しているファージにおいて該コーディング配列を発現し; 次いで f)ファージを固定抗原で選り分けることによって抗原に特異的な認識分子を 選択する、ステップを特徴とする方法。 21.抗原に特異的である、請求項1から13に記載の認識分子の製造方法で あって: a)認識分子またはその先駆体をコードするDNA配列を単離し; b)必要に応じて、1個またはそれ以上の塩基置換、欠失または挿入を導入す ることによって該分子またはその先駆体を修飾し; c)このようにして得られた、必要に応じて修飾された、DNA配列を適当な 宿主に移入し;次いで d)宿主内でDNA配列を発現する、ステップを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201788.5 | 1996-06-27 | ||
EP96201788 | 1996-06-27 | ||
PCT/EP1997/003488 WO1997049805A2 (en) | 1996-06-27 | 1997-06-27 | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008195891A Division JP2009040780A (ja) | 1996-06-27 | 2008-07-30 | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000515002A true JP2000515002A (ja) | 2000-11-14 |
Family
ID=8224120
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09535650A Pending JP2000515002A (ja) | 1996-06-27 | 1997-06-27 | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
JP2008195891A Withdrawn JP2009040780A (ja) | 1996-06-27 | 2008-07-30 | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008195891A Withdrawn JP2009040780A (ja) | 1996-06-27 | 2008-07-30 | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0937140B1 (ja) |
JP (2) | JP2000515002A (ja) |
AT (1) | ATE374248T1 (ja) |
AU (1) | AU740043B2 (ja) |
CA (1) | CA2258518C (ja) |
DE (1) | DE69738166T2 (ja) |
DK (1) | DK0937140T3 (ja) |
ES (1) | ES2294799T3 (ja) |
WO (1) | WO1997049805A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021502063A (ja) * | 2017-10-31 | 2021-01-28 | フエー・イー・ベー・フエー・ゼツト・ウエー | 新規抗原結合性キメラタンパク質とその方法及び使用 |
Families Citing this family (222)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1134231B1 (en) | 2000-03-14 | 2009-04-15 | Unilever N.V. | Antibody heavy chain variable domains against human dietary lipases, and their uses |
WO2003025020A1 (fr) * | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Procede pour creer une banque d'anticorps de chameaux |
EP1461085A2 (en) * | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugates useful for treatment of tumours |
CA2472927A1 (en) | 2002-01-10 | 2003-07-17 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | A novel splice variant of myd88 and uses thereof |
JP2006524036A (ja) | 2002-11-08 | 2006-10-26 | アブリンクス エン.ヴェー. | 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用 |
WO2005044858A1 (en) | 2003-11-07 | 2005-05-19 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
AU2003286003B2 (en) | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CN101724071A (zh) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
AU2006205900B8 (en) | 2005-01-14 | 2012-04-05 | Ablynx N.V. | Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets |
AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
NZ563392A (en) | 2005-05-20 | 2009-12-24 | Ablynx Nv | Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders |
WO2007082899A1 (en) | 2006-01-17 | 2007-07-26 | Vib Vzw | Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
TW200744634A (en) * | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
CA2672201A1 (en) | 2006-11-07 | 2008-05-15 | Vib Vzw | Use of myb gene to diagnose and treat t-cell acute lumphoblastic leukemia |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
PL2308514T3 (pl) | 2007-03-23 | 2013-11-29 | To Bbb Holding B V | Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg |
US10214588B2 (en) | 2007-07-03 | 2019-02-26 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating CDR and/or FR positions |
DK2567709T3 (en) | 2007-11-02 | 2018-03-12 | Novartis Ag | Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) |
EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
GB0800277D0 (en) | 2008-01-08 | 2008-02-13 | Imagination Tech Ltd | Video motion compensation |
GB2470328A (en) | 2008-03-05 | 2010-11-17 | Ablynx Nv | Novel antigen binding dimer complexes, methods of making and uses thereof |
KR101568042B1 (ko) | 2008-03-31 | 2015-11-10 | 가부시끼가이샤 히다치 세이사꾸쇼 | 감쇠력 조정식 완충기 |
GB0809069D0 (en) | 2008-05-19 | 2008-06-25 | Univ Leuven Kath | Gene signatures |
CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
JP6034023B2 (ja) | 2008-05-16 | 2016-11-30 | アブリンクス エン.ヴェー. | Cxcr4及び他のgpcrに指向性を有するアミノ酸配列及びそれを含む化合物 |
AR071874A1 (es) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
CA2739357A1 (en) | 2008-09-23 | 2010-04-08 | Wyeth Llc | Methods for predicting production of activating signals by cross-linked binding proteins |
GB0900425D0 (en) | 2009-01-12 | 2009-02-11 | Ucb Pharma Sa | Biological products |
US9085795B2 (en) | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
WO2011026948A1 (en) | 2009-09-03 | 2011-03-10 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
AU2010243551B2 (en) | 2009-04-30 | 2015-03-26 | Ablynx Nv | Method for the production of domain antibodies |
EP2448966B1 (en) | 2009-07-03 | 2018-11-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
HUE051430T2 (hu) | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
EP2459053A2 (en) | 2009-07-28 | 2012-06-06 | F. Hoffmann-La Roche AG | Non-invasive in vivo optical imaging method |
WO2011027132A1 (en) | 2009-09-03 | 2011-03-10 | Cancer Research Technology Limited | Clec14a inhibitors |
US9234037B2 (en) | 2009-10-27 | 2016-01-12 | Ucb Biopharma Sprl | Method to generate antibodies to ion channels |
CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
CA2784610C (en) | 2009-12-23 | 2020-07-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
WO2011083140A1 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Immunoglobulin single variable domain directed against human cxcr4 |
CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
PL2533761T3 (pl) | 2010-02-11 | 2019-09-30 | Ablynx N.V. | Sposoby i kompozycje do wytwarzania aerozoli |
EP2553449A2 (en) | 2010-03-26 | 2013-02-06 | Westfälische Wilhelms-Universität Münster | Substitute therapy for glucocorticoids |
US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
GB201105584D0 (en) | 2011-04-01 | 2011-05-18 | Imp Innovations Ltd | Cancer methods |
JP6145404B2 (ja) | 2010-05-07 | 2017-06-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エクスビボでの細胞の検出のための診断的方法 |
WO2011161263A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Pharmaceutical compositions for cutaneous administration |
AU2011273360A1 (en) | 2010-07-02 | 2013-02-07 | Vib Vzw | The role of Fragile X mental retardation gene and protein in cancer metastasis |
GB201012845D0 (en) | 2010-07-30 | 2010-09-15 | Vib Vzw | Inhibition of dicer function for treatment of cancer |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
WO2012056000A1 (en) | 2010-10-29 | 2012-05-03 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
GB201018602D0 (en) | 2010-11-04 | 2010-12-22 | Vib Vzw | MMP8 inactivating antigen binding proteins |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
US20140099264A1 (en) | 2011-03-07 | 2014-04-10 | F. Hoffman-La Roche Ag | Means and methods for in vivo testing of therapeutic antibodies |
WO2012122590A1 (en) | 2011-03-14 | 2012-09-20 | Cellmid Limited | Antibody recognizing n-domain of midkine |
US9468679B2 (en) | 2011-03-28 | 2016-10-18 | Ablynx N.V. | Method for producing solid formulations comprising immunoglobulin single variable domains |
WO2012152823A1 (en) | 2011-05-09 | 2012-11-15 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
AU2012264809B2 (en) | 2011-05-27 | 2017-05-04 | Ablynx Nv | Inhibition of bone resorption with RANKL binding peptides |
US9580480B2 (en) | 2011-05-31 | 2017-02-28 | Massachusetts Institute Of Technology | Cell-directed synthesis of multifunctional nanopatterns and nanomaterials |
AU2012269720B2 (en) | 2011-06-13 | 2015-01-22 | Csl Limited | Antibodies against G-CSFR and uses thereof |
IN2014CN00437A (ja) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
GB201115529D0 (en) | 2011-09-08 | 2011-10-26 | Imp Innovations Ltd | Antibodies, uses and methods |
WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
EP3311837A1 (en) | 2011-09-23 | 2018-04-25 | Ablynx NV | Prolonged inhibition of interleukin-6 mediated signaling |
US9265817B2 (en) | 2011-10-28 | 2016-02-23 | Patrys Limited | PAT-LM1 epitopes and methods for using same |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2013079973A1 (en) | 2011-12-02 | 2013-06-06 | Di Cara Danielle Marie | Antibodies against hgf - receptor and uses |
US20150301068A1 (en) | 2012-01-30 | 2015-10-22 | Vib Vzw | Means and method for diagnosis and treatment of alzheimer's disease |
WO2013121042A1 (en) | 2012-02-16 | 2013-08-22 | Vib Vzw | PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JP6411333B2 (ja) | 2012-05-24 | 2018-10-24 | ブイアイビー ブイゼットダブリュVib Vzw | 腫瘍関連マクロファージのターゲティングおよびinvivoイメージング用抗マクロファージマンノース受容体単一可変ドメイン |
US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
WO2014001557A1 (en) | 2012-06-28 | 2014-01-03 | Ucb Pharma S.A. | A method for identifying compounds of therapeutic interest |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
CA2899693C (en) | 2013-01-30 | 2023-03-14 | Vib Vzw | Novel chimeric polypeptides for screening and drug discovery purposes |
PT2953973T (pt) | 2013-02-05 | 2019-10-25 | Univ Brussel Vrije | Agentes de ligação do receptor muscarínico de acetilololina e usos |
US9340618B2 (en) | 2013-02-07 | 2016-05-17 | Csl Limited | IL-11R binding proteins |
US9617339B2 (en) | 2013-03-15 | 2017-04-11 | Vib Vzw | Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
EP2992101B1 (en) | 2013-04-29 | 2018-10-10 | Agrosavfe N.V. | Agrochemical compositions comprising antibodies binding to sphingolipids |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
DE112014004537T5 (de) | 2013-10-01 | 2016-07-21 | Kymab Limited | Tiermodelle und therapeutische Moleküle |
EP3530286A1 (en) | 2013-11-28 | 2019-08-28 | CSL Limited | Method of treating diabetic nephropathy |
EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
PL3082860T3 (pl) | 2013-12-18 | 2021-06-14 | Csl Limited | Sposób leczenia ran |
WO2015121092A1 (en) | 2014-01-30 | 2015-08-20 | Vib Vzw | Opioid receptor binding agents and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
EP3194976B1 (en) | 2014-07-22 | 2020-04-01 | Vib Vzw | Methods to select agents that stabilize protein complexes |
EP3718574A1 (en) | 2014-07-29 | 2020-10-07 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
EP3180037A1 (en) | 2014-07-29 | 2017-06-21 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
EP3209697A4 (en) | 2014-10-23 | 2018-05-30 | La Trobe University | Fn14-binding proteins and uses thereof |
EP3215624B1 (en) | 2014-11-05 | 2023-11-29 | Biotalys NV | Transgenic plant comprising a polynucleotide encoding a variable domain of heavy-chain antibody |
WO2016094962A1 (en) | 2014-12-19 | 2016-06-23 | Monash University | Il-21 antibodies |
JP6862343B2 (ja) | 2014-12-19 | 2021-04-21 | アブリンクス エン.ヴェー. | システイン結合ナノボディダイマー |
GB201501004D0 (en) | 2015-01-21 | 2015-03-04 | Cancer Rec Tech Ltd | Inhibitors |
EP3325020B1 (en) | 2015-07-17 | 2022-01-12 | Vrije Universiteit Brussel | Radiolabelled antibody fragments for use in treating cancer |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
SG11201803976VA (en) | 2015-11-27 | 2018-06-28 | Ablynx Nv | Polypeptides inhibiting cd40l |
EP3386542B1 (en) | 2015-12-10 | 2020-11-18 | Katholieke Universiteit Leuven | Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device |
WO2017182605A1 (en) | 2016-04-22 | 2017-10-26 | Université Libre de Bruxelles | A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells |
US11243214B2 (en) | 2016-04-22 | 2022-02-08 | Université Libre de Bruxelles | Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells |
US20190127447A1 (en) | 2016-05-02 | 2019-05-02 | Ablynx N.V. | Treatment of rsv infection |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
CN110023339A (zh) | 2016-09-23 | 2019-07-16 | Csl有限公司 | 凝血因子结合蛋白及其应用 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
EP3589725A1 (en) | 2017-02-28 | 2020-01-08 | Vib Vzw | Means and methods for oral protein delivery |
WO2018192974A1 (en) | 2017-04-18 | 2018-10-25 | Université Libre de Bruxelles | Biomarkers and targets for proliferative diseases |
WO2018206734A1 (en) | 2017-05-11 | 2018-11-15 | Vib Vzw | Glycosylation of variable immunoglobulin domains |
US11261260B2 (en) | 2017-06-02 | 2022-03-01 | Merck Patent Gmbh | ADAMTS binding immunoglobulins |
WO2018220235A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Mmp13 binding immunoglobulins |
JP7249961B2 (ja) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adamts5、mmp13およびアグリカンに結合するポリペプチド |
AR112069A1 (es) | 2017-06-02 | 2019-09-18 | Ablynx Nv | Inmunoglobulinas que fijan aggrecan |
GB201709379D0 (en) | 2017-06-13 | 2017-07-26 | Univ Leuven Kath | Humanised ADAMTS13 binding antibodies |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
CA3067247A1 (en) | 2017-07-11 | 2019-01-17 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
WO2019016237A1 (en) | 2017-07-19 | 2019-01-24 | Vib Vzw | AGENTS FOR CONNECTING TO SERUM ALBUMIN |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | ANTI-NUCLEOLIN ANTIBODIES |
WO2019067015A1 (en) | 2017-09-29 | 2019-04-04 | City Of Hope | RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA |
US11466073B2 (en) | 2017-10-18 | 2022-10-11 | Csl Limited | Human serum albumin variants and uses thereof |
US10017560B1 (en) | 2017-11-16 | 2018-07-10 | King Saud University | Nanobody against begomoviruses |
PL3717011T3 (pl) | 2017-11-29 | 2023-03-27 | Csl Limited | Sposób leczenia lub zapobiegania uszkodzeniu niedokrwienno- reperfuzyjnemu |
JP2021505207A (ja) | 2017-12-05 | 2021-02-18 | セリアド エス.アー.Celyad S.A. | Nkg2dベースの受容体を発現する免疫細胞のフラトリサイドの減少 |
JP2021505208A (ja) | 2017-12-05 | 2021-02-18 | セリアド エス.アー.Celyad S.A. | 養子細胞療法用細胞の持続性を向上するための組成物および方法 |
KR20200104333A (ko) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Tigit에 대한 단일-도메인 항체 및 이의 변이체 |
US11713353B2 (en) | 2018-01-15 | 2023-08-01 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against PD-1 |
WO2019155041A1 (en) | 2018-02-12 | 2019-08-15 | Vib Vzw | Gβγ COMPLEX ANTIBODIES AND USES THEREOF |
WO2019166622A1 (en) | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
CN112384527B (zh) | 2018-03-23 | 2023-06-27 | 布鲁塞尔自由大学 | Wnt信号传递激动剂分子 |
EP3773665A1 (en) | 2018-03-27 | 2021-02-17 | UMC Utrecht Holding B.V. | Targeted thrombolysis for treatment of microvascular thrombosis |
EP3774917A4 (en) | 2018-03-30 | 2022-01-19 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF |
US20210221864A1 (en) | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
GB201814451D0 (en) | 2018-09-05 | 2018-10-17 | Valerie Nicholas Carl Kristoffer | Methods |
US20220276244A1 (en) | 2019-04-29 | 2022-09-01 | Confo Therapeutics N.V. | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
EP3962599A1 (en) | 2019-04-30 | 2022-03-09 | Vib Vzw | Cystic fibrosis transmembrane conductance regulator stabilizing agents |
EP3976650A1 (en) | 2019-05-28 | 2022-04-06 | Vib Vzw | Cancer treatment by targeting plexins in the immune compartment |
WO2020239934A1 (en) | 2019-05-28 | 2020-12-03 | Vib Vzw | Cd8+ t-cells lacking plexins and their application in cancer treatment |
GB2584441A (en) | 2019-06-03 | 2020-12-09 | Fenomark Diagnostics Ab | Medical uses, methods and uses |
WO2021012195A1 (zh) * | 2019-07-23 | 2021-01-28 | 源道隆(苏州)医学科技有限公司 | 可结合sftsv的纳米抗体及其应用 |
WO2021078786A1 (en) | 2019-10-21 | 2021-04-29 | Vib Vzw | Nanodisc-specific antigen-binding chimeric proteins |
MX2022005678A (es) | 2019-11-11 | 2022-10-18 | Ibi Ag Innovative Bio Insecticides Ltd | Nanocuerpos para el control de insectos y usos de los mismos. |
US20220411495A1 (en) | 2019-11-27 | 2022-12-29 | Vib Vzw | Positive allosteric modulators of the calcium-sensing receptor |
GB201918279D0 (en) | 2019-12-12 | 2020-01-29 | Vib Vzw | Glycosylated single chain immunoglobulin domains |
WO2021123360A1 (en) | 2019-12-20 | 2021-06-24 | Vib Vzw | Nanobody exchange chromatography |
JP2023508023A (ja) | 2019-12-20 | 2023-02-28 | ハドソン インスティチュート オブ メディカル リサーチ | Cxcl10結合タンパク質及びその使用 |
WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
IL295892A (en) | 2020-02-25 | 2022-10-01 | Vib Vzw | Leucine-rich repeat kinase 2 allosteric modulators |
WO2021198396A1 (en) | 2020-03-31 | 2021-10-07 | Biotalys NV | Anti-fungal polypeptides |
US20230279115A1 (en) | 2020-04-22 | 2023-09-07 | Mabwell (shanghai) Bioscience Co., Ltd. | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
WO2021229104A1 (en) | 2020-05-15 | 2021-11-18 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
WO2022023583A1 (en) | 2020-07-31 | 2022-02-03 | Biotalys NV | Expression host |
WO2022035998A1 (en) | 2020-08-11 | 2022-02-17 | City Of Hope | Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells |
WO2022063957A1 (en) | 2020-09-24 | 2022-03-31 | Vib Vzw | Biomarker for anti-tumor therapy |
CA3196737A1 (en) | 2020-09-24 | 2022-03-31 | Massimiliano Mazzone | Combination of p2y6 inhibitors and immune checkpoint inhibitors |
IL301581A (en) | 2020-09-25 | 2023-05-01 | Ablynx Nv | Polypeptides comprising single immunoglobulin variable sites targeting 13-IL and OX40L |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
WO2022117572A2 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | An ltbr agonist in combination therapy against cancer |
WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
GB202020502D0 (en) | 2020-12-23 | 2021-02-03 | Vib Vzw | Antibody composistion for treatment of corona virus infection |
EP4267618A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Non-blocking human ccr8 binders |
EP4267621A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Murine cross-reactive human ccr8 binders |
CA3206304A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Human ccr8 binders |
GB2603166A (en) | 2021-01-29 | 2022-08-03 | Thelper As | Therapeutic and Diagnostic Agents and Uses Thereof |
CN117794566A (zh) | 2021-02-05 | 2024-03-29 | Vib研究所 | 沙贝病毒结合剂 |
US20240101647A1 (en) | 2021-02-05 | 2024-03-28 | Vib Vzw | Sarbecovirus binders |
WO2022175392A1 (en) | 2021-02-17 | 2022-08-25 | Vib Vzw | Inhibition of slc4a4 in the treatment of cancer |
EP4294516A1 (en) | 2021-02-19 | 2023-12-27 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
WO2022199804A1 (en) | 2021-03-24 | 2022-09-29 | Vib Vzw | Nek6 inhibition to treat als and ftd |
WO2022242892A1 (en) | 2021-05-17 | 2022-11-24 | Université de Liège | Anti-cd38 single-domain antibodies in disease monitoring and treatment |
WO2022268993A1 (en) | 2021-06-23 | 2022-12-29 | Vib Vzw | Means and methods for selection of specific binders |
CN117580865A (zh) | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
CA3227972A1 (en) | 2021-07-30 | 2023-02-02 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibodies and applications thereof |
WO2023016828A2 (en) | 2021-07-30 | 2023-02-16 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
WO2023057601A1 (en) | 2021-10-06 | 2023-04-13 | Biotalys NV | Anti-fungal polypeptides |
WO2023079137A1 (en) | 2021-11-05 | 2023-05-11 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
WO2023135198A1 (en) | 2022-01-12 | 2023-07-20 | Vib Vzw | Human ntcp binders for therapeutic use and liver-specific targeted delivery |
GB202201137D0 (en) | 2022-01-28 | 2022-03-16 | Thelper As | Therapeutic and diagnostic agents and uses thereof |
WO2023148291A1 (en) | 2022-02-02 | 2023-08-10 | Biotalys NV | Methods for genome editing |
WO2023148397A1 (en) | 2022-02-07 | 2023-08-10 | Vib Vzw | Engineered stabilizing aglycosylated fc-regions |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2023213751A1 (en) | 2022-05-02 | 2023-11-09 | Umc Utrecht Holding B.V | Single domain antibodies for the detection of plasmin-cleaved vwf |
WO2023222825A1 (en) | 2022-05-18 | 2023-11-23 | Vib Vzw | Sarbecovirus spike s2 subunit binders |
WO2024008755A1 (en) | 2022-07-04 | 2024-01-11 | Vib Vzw | Blood-cerebrospinal fluid barrier crossing antibodies |
WO2024008904A2 (en) | 2022-07-08 | 2024-01-11 | Novo Nordisk A/S | Highly potent isvd compounds capable of substituting for fviii(a) |
WO2024049951A1 (en) | 2022-08-31 | 2024-03-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of fusion polypeptides for treatment of sickle cell disease |
WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2162823T5 (es) * | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
EP0739981A1 (en) * | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
-
1997
- 1997-06-27 CA CA2258518A patent/CA2258518C/en not_active Expired - Lifetime
- 1997-06-27 EP EP97931749A patent/EP0937140B1/en not_active Expired - Lifetime
- 1997-06-27 WO PCT/EP1997/003488 patent/WO1997049805A2/en active IP Right Grant
- 1997-06-27 DE DE69738166T patent/DE69738166T2/de not_active Expired - Lifetime
- 1997-06-27 ES ES97931749T patent/ES2294799T3/es not_active Expired - Lifetime
- 1997-06-27 DK DK97931749T patent/DK0937140T3/da active
- 1997-06-27 JP JP09535650A patent/JP2000515002A/ja active Pending
- 1997-06-27 AU AU35399/97A patent/AU740043B2/en not_active Expired
- 1997-06-27 AT AT97931749T patent/ATE374248T1/de active
-
2008
- 2008-07-30 JP JP2008195891A patent/JP2009040780A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021502063A (ja) * | 2017-10-31 | 2021-01-28 | フエー・イー・ベー・フエー・ゼツト・ウエー | 新規抗原結合性キメラタンパク質とその方法及び使用 |
Also Published As
Publication number | Publication date |
---|---|
AU3539997A (en) | 1998-01-14 |
WO1997049805A2 (en) | 1997-12-31 |
EP0937140A2 (en) | 1999-08-25 |
WO1997049805A3 (en) | 1998-02-19 |
CA2258518C (en) | 2011-11-22 |
JP2009040780A (ja) | 2009-02-26 |
CA2258518A1 (en) | 1997-12-31 |
DE69738166T2 (de) | 2008-06-19 |
ES2294799T3 (es) | 2008-04-01 |
DE69738166D1 (de) | 2007-11-08 |
AU740043B2 (en) | 2001-10-25 |
ATE374248T1 (de) | 2007-10-15 |
EP0937140B1 (en) | 2007-09-26 |
DK0937140T3 (da) | 2008-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000515002A (ja) | 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子 | |
JP6356199B2 (ja) | 血漿カリクレイン結合タンパク質 | |
ES2162823T5 (es) | Inmunoglobulinas desprovistas de cadenas ligeras. | |
TWI796328B (zh) | B7-h3抗體、其抗原結合片段及其醫藥用途 | |
KR101451546B1 (ko) | Gm-csf 수용체에 대한 결합 성분 | |
WO1997049805A9 (en) | Recognition molecules interacting specifically with the active site or cleft of a target molecule | |
KR102502293B1 (ko) | 혈장 칼리크레인 결합 단백질 | |
RU2704232C2 (ru) | Однодоменные антитела, направленные против фактора некроза опухолей альфа, и их применение | |
JP4992068B2 (ja) | 超高親和性中和抗体 | |
JP2004529647A (ja) | ヒトtimp−1抗体 | |
TW201103560A (en) | Use of an anti-Tau pS422 antibody for the treatment of brain diseases | |
EP1558646A2 (en) | Single domain antibodies directed against interferon- gamma and uses thereof | |
CN112390879A (zh) | 靶向SARS-CoV-2的抗体及其制备方法和应用 | |
JPH06502526A (ja) | 結合ドメイン | |
CN107108730A (zh) | Il‑17a结合蛋白 | |
CN111201246A (zh) | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 | |
Foti et al. | Rabbit monoclonal Fab derived from a phage display library | |
US20040248201A1 (en) | Recognition molecules interacting specifically with the active site or cleft of a target molecule | |
KR20230035079A (ko) | 응고인자 xi(fxi) 결합 단백질 | |
CN117321076A (zh) | 中和SARS-CoV-2的单结构域抗体 | |
WO2019096294A1 (zh) | 凝血酶抗体、其抗原结合片段及医药用途 | |
JP2023529557A (ja) | 抗enpp1抗体の阻害 | |
TW202200623A (zh) | 對炎症性腸病之治療用抗體 | |
AU2013200962B2 (en) | Binding member for GM-CSF receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040427 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070417 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080401 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080730 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20080630 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081106 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090402 |